{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:56:00Z","timestamp":1790207760571,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA285580-01"],"award-info":[{"award-number":["R01-CA285580-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RSG-23-1151048-01-IBCD"],"award-info":[{"award-number":["RSG-23-1151048-01-IBCD"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","award":["RSG-23-1151048-01-IBCD"],"award-info":[{"award-number":["RSG-23-1151048-01-IBCD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PID2024-160007OB-I00"],"award-info":[{"award-number":["PID2024-160007OB-I00"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101077312"],"award-info":[{"award-number":["101077312"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["RYC2022-036321-I"],"award-info":[{"award-number":["RYC2022-036321-I"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["RA220126"],"award-info":[{"award-number":["RA220126"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA22125"],"award-info":[{"award-number":["CA22125"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["R01-CA285580-01"],"award-info":[{"award-number":["R01-CA285580-01"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jhepr.2026.101850","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:23:27Z","timestamp":1775316207000},"page":"101850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of the stromal and immune microenvironment in intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9731-3913","authenticated-orcid":false,"given":"Silvia","family":"Affo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-611X","authenticated-orcid":false,"given":"Daniela","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101850_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.101850_bib2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib5","first-page":"255","article-title":"Translating cancer genomics for precision oncology in biliary tract cancers","volume":"28","author":"Haber","year":"2019","journal-title":"Discov Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib6","article-title":"Cell of origin in biliary tract cancers and clinical implications","volume":"3","author":"Moeini","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101850_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2026.101850_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101850_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.101850_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.101850_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12876-016-0565-6","article-title":"A significant cancer burden and high mortality of intrahepatic cholangiocarcinoma in Thailand: a nationwide database study","volume":"17","author":"Treeprasertsuk","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101850_bib13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib15","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhepr.2026.101850_bib16","doi-asserted-by":"crossref","unstructured":"Oh D-Y, Ruth He A, Qin S, et al: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid; 1:EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"10.1016\/j.jhepr.2026.101850_bib17","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101850_bib18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells12060846","article-title":"Heterogeneity of cholangiocarcinoma immune biology","volume":"12","author":"Vita","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2026.101850_bib23","article-title":"Applications of single-cell multi-omics in liver cancer","volume":"6","author":"Peeters","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101850_bib24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2026.101850_bib25","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib26","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2026.101850_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jhepr.2026.101850_bib28","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101850_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib30","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101850_bib31","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101850_bib32","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101850_bib33","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101850_bib34","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-21-1157","article-title":"Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101850_bib35","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/s41467-022-35291-5","article-title":"Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101850_bib36","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","article-title":"Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"75","author":"Ma","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101850_bib38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.32150","article-title":"The immunogenomic landscape of resected intrahepatic cholangiocarcinoma","volume":"75","author":"Carapeto","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib39","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/hep.30493","article-title":"Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma","volume":"69","author":"Goeppert","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib40","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2026.101850_bib41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40364-024-00648-z","article-title":"Spatial resolved transcriptomics reveals distinct cross-talk between cancer cells and tumor-associated macrophages in intrahepatic cholangiocarcinoma","volume":"12","author":"Dong","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.jhepr.2026.101850_bib42","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1158\/2326-6066.CIR-21-1101","article-title":"Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis","volume":"10","author":"Bao","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jhepr.2026.101850_bib43","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ymthe.2025.02.019","article-title":"Multiple-omics analysis reveals a dedifferentiation-immune loop in intrahepatic cholangiocarcinoma","volume":"33","author":"Ruan","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2026.101850_bib44","article-title":"Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area","volume":"12","author":"Zuyin","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jhepr.2026.101850_bib45","doi-asserted-by":"crossref","first-page":"eadf6493","DOI":"10.1126\/science.adf6493","article-title":"Deterministic reprogramming of neutrophils within tumors","volume":"383","author":"Ng","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2026.101850_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101850_bib47","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jhep.2022.05.043","article-title":"Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target","volume":"77","author":"Alvisi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib48","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","article-title":"Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"76","author":"Ding","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib49","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/ni.3290","article-title":"Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma","volume":"16","author":"Finkin","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhepr.2026.101850_bib50","first-page":"501","article-title":"Spatial and maturity heterogeneity of tertiary lymphoid structures shapes immune microenvironment and progression in prostate cancer","volume":"5","author":"Wang","year":"2025","journal-title":"J Natl Cancer Cent"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101850_bib51","first-page":"2248","article-title":"Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome","volume":"13","author":"Milardi","year":"2023","journal-title":"Canncer Discov"},{"key":"10.1016\/j.jhepr.2026.101850_bib52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004892","article-title":"Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities","volume":"10","author":"Lin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.101850_bib54","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-23-0282","article-title":"An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS-mutant intrahepatic cholangiocarcinoma","volume":"13","author":"Zhang","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101850_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhepr.2026.101850_bib56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib57","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/2159-8290.CD-21-1640","article-title":"Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101850_bib58","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jhep.2024.02.008","article-title":"Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma","volume":"80","author":"Tomlinson","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib59","article-title":"KRAS withdrawal in cholangiocarcinoma leads to immune infiltration and tumor regression","volume":"13","author":"Qiao","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jhepr.2026.101850_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000632","article-title":"Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging","volume":"9","author":"Baretti","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101850_bib61","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH inhibits IFNgamma-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101850_bib62","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2468-1253(23)00111-5","article-title":"Fibroblasts in liver cancer: functions and therapeutic translation","volume":"8","author":"Affo","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib63","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101850_bib64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/a-2551-0724","article-title":"Hepatic stellate cells functional heterogeneity in liver cancer","volume":"45","author":"Sererols-Vinas","year":"2025","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101850_bib66","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/0008-5472.CAN-12-2130","article-title":"Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma","volume":"73","author":"Mertens","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101850_bib67","article-title":"Insights into the relevance of targeting fibroblasts to control cancer","volume":"6","author":"Boeker","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib68","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2018.12.004","article-title":"Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma","volume":"70","author":"Cadamuro","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib69","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/HEP.0000000000000206","article-title":"Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma","volume":"79","author":"Cantallops Vila","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib70","article-title":"New insights on the role of vascular endothelial growth factor in biliary pathophysiology","volume":"3","author":"Mariotti","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101850_bib71","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","article-title":"Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma","volume":"73","author":"Zhang","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib72","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3389\/fimmu.2018.02270","article-title":"Extracellular vesicles in hepatobiliary malignancies","volume":"9","author":"Lapitz","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101850_bib73","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/hep.28735","article-title":"Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model","volume":"65","author":"Li","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib74","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1038\/s41598-023-34676-w","article-title":"Ceramide present in cholangiocarcinoma-derived extracellular vesicle induces a pro-inflammatory state in monocytes","volume":"13","author":"Oliviero","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101850_bib75","first-page":"8681","article-title":"Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells","volume":"15","author":"Zeng","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jhepr.2026.101850_bib76","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13543784.2021.1865308","article-title":"Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhepr.2026.101850_bib77","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhepr.2026.101850_bib78","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","article-title":"Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma","volume":"43","author":"Huang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101850_bib79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41416-021-01569-6","article-title":"Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma","volume":"126","author":"Lan","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.101850_bib80","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ajpath.2024.07.009","article-title":"Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma: insights into origins, heterogeneity, lymphangiogenesis, and peritoneal metastasis","volume":"195","author":"Aff\u1f78","year":"2025","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2026.101850_bib81","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41392-025-02347-z","article-title":"NADPH oxidase 1\/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts","volume":"10","author":"Amengual","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jhepr.2026.101850_bib82","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1055\/s-0040-1705109","article-title":"Liver matrix in benign and malignant biliary tract disease","volume":"40","author":"Fabris","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101850_bib83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/19336918.2015.1008331","article-title":"Tenascin C in metastasis: a view from the invasive front","volume":"9","author":"Lowy","year":"2015","journal-title":"Cell Adh Migr"},{"key":"10.1016\/j.jhepr.2026.101850_bib84","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.3390\/curroncol30040319","article-title":"Cancer-associated fibroblasts and extracellular matrix: therapeutical strategies for modulating the cholangiocarcinoma microenvironment","volume":"30","author":"Minini","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib85","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000502","article-title":"Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy","volume":"8","author":"Burchard","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101850_bib86","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2023.11.302","article-title":"Fibroblast-derived lysyl oxidase increases oxidative phosphorylation and stemness in cholangiocarcinoma","volume":"166","author":"Lewinska","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101850_bib87","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.ccell.2024.08.020","article-title":"Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation","volume":"42","author":"Gao","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101850_bib88","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.ccell.2024.08.022","article-title":"Universal and tissue-specific fibroblasts in chronic inflammation and cancer","volume":"42","author":"Koplev","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101850_bib89","doi-asserted-by":"crossref","first-page":"102611","DOI":"10.1016\/j.xcrm.2026.102611","article-title":"DeCAF defines clinical fibroblast subtypes and multidimensional tumor-stroma crosstalk shaping prognosis and immunotherapy response","volume":"7","author":"Peng","year":"2026","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib90","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146987","article-title":"Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts","volume":"131","author":"Bhattacharjee","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2026.101850_bib91","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101850_bib92","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101850_bib93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12014-019-9257-x","article-title":"Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure","volume":"16","author":"Carpino","year":"2019","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.jhepr.2026.101850_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-05645-2","article-title":"Activated cancer-associated fibroblasts correlate with poor survival and decreased lymphocyte infiltration in infiltrative type distal cholangiocarcinoma","volume":"15","author":"Lim","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101850_bib95","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1793005","article-title":"Prediction of prognosis and recurrence of bladder cancer by ECM-related genes","volume":"2022","author":"Zhao","year":"2022","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jhepr.2026.101850_bib96","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1038\/s41598-025-88376-8","article-title":"Identification of an extracellular matrix signature for predicting prognosis and sensitivity to therapy of patients with gastric cancer","volume":"15","author":"Xu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101850_bib97","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/01.MP.0000086860.65672.73","article-title":"Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma","volume":"16","author":"Aishima","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhepr.2026.101850_bib98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-4598-9-13","article-title":"Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker","volume":"9","author":"Utispan","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhepr.2026.101850_bib99","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.yexmp.2014.10.007","article-title":"Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications","volume":"97","author":"Sirica","year":"2014","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.jhepr.2026.101850_bib100","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3892\/ijo.2012.1530","article-title":"Periostin activates integrin alpha5beta1 through a PI3K\/AKT-dependent pathway in invasion of cholangiocarcinoma","volume":"41","author":"Utispan","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib101","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/hep4.1114","article-title":"Periostin promotes malignant potential by induction of epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma","volume":"1","author":"Mino","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101850_bib102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41419-017-0226-x","article-title":"Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of beta-Catenin","volume":"9","author":"Zheng","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2026.101850_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054748","article-title":"Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by osteopontin overexpression in the tumor stroma","volume":"24","author":"Cadamuro","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2026.101850_bib104","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ceb.2010.08.015","article-title":"Dynamic interplay between the collagen scaffold and tumor evolution","volume":"22","author":"Egeblad","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jhepr.2026.101850_bib105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/jcrt.JCRT_489_17","article-title":"Deciphering the \"Collagen code\" in tumor progression","volume":"17","author":"Gupta","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.jhepr.2026.101850_bib106","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","article-title":"Tumor-associated macrophages restrict CD8(+) T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhepr.2026.101850_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9284","article-title":"Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis","volume":"11","author":"Yang","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib108","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib109","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1478-3231.2012.02783.x","article-title":"Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers","volume":"32","author":"Xu","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101850_bib110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.surg.2024.03.024","article-title":"Intrahepatic cholangiocarcinoma with arterial phase hyperenhancement and specialized tumor microenvironment associated with good prognosis after radical resection: a single-center retrospective study","volume":"176","author":"Mashiko","year":"2024","journal-title":"Surgery"},{"key":"10.1016\/j.jhepr.2026.101850_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12071086","article-title":"Translational value of tumor-associated lymphangiogenesis in cholangiocarcinoma","volume":"12","author":"Cadamuro","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib112","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12885-019-5420-z","article-title":"Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma","volume":"19","author":"Sha","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.101850_bib113","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1186\/s12967-024-05750-2","article-title":"Integrative multi-omics analysis reveals the role of tumor-associated endothelial cells and their signature in prognosis of intrahepatic cholangiocarcinoma","volume":"22","author":"Jiang","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib114","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fmed.2019.00293","article-title":"Inflammation and progression of cholangiocarcinoma: role of angiogenic and lymphangiogenic mechanisms","volume":"6","author":"Roy","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhepr.2026.101850_bib115","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ajg.2009.674","article-title":"Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma","volume":"105","author":"Thelen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101850_bib116","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.7150\/ijbs.26045","article-title":"Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis","volume":"14","author":"Sha","year":"2018","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jhepr.2026.101850_bib117","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jhep.2025.03.035","article-title":"Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response","volume":"83","author":"Cui","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib118","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2326-6066.CIR-23-0486","article-title":"Reprogramming the intrahepatic cholangiocarcinoma immune microenvironment by chemotherapy and CTLA-4 blockade enhances anti-PD-1 therapy","volume":"12","author":"Chen","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jhepr.2026.101850_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25074031","article-title":"The differential effect of senolytics on SASP cytokine secretion and regulation of EMT by CAFs","volume":"25","author":"Bogdanova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2026.101850_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11216498","article-title":"Cancer-associated fibroblasts in cholangiocarcinoma: current knowledge and possible implications for therapy","volume":"11","author":"Montori","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib121","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","article-title":"Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction","volume":"4","author":"Amor","year":"2024","journal-title":"Nat Aging"},{"key":"10.1016\/j.jhepr.2026.101850_bib122","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","article-title":"Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis","volume":"81","author":"Yashaswini","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101850_bib123","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1021\/acsnano.0c00417","article-title":"Photothermal depletion of cancer-associated fibroblasts normalizes tumor stiffness in desmoplastic cholangiocarcinoma","volume":"14","author":"Nicolas-Boluda","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jhepr.2026.101850_bib124","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001545","article-title":"Laser-activated nanoparticles rewire tumor microenvironment enhancing PD-1 blockade and T cell response in cholangiocarcinoma","author":"Minini","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib125","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/hep.20966","article-title":"Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells","volume":"42","author":"Isomoto","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib126","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101850_bib127","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2026.101850_bib128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fcell.2020.00152","article-title":"Targeting the HGF\/MET axis in cancer therapy: challenges in resistance and opportunities for improvement","volume":"8","author":"Huang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jhepr.2026.101850_bib129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajpath.2024.10.021","article-title":"Development of CAR-T therapies and personalized vaccines for the treatment of cholangiocarcinoma: current progress, mechanisms of action, and challenges","volume":"195","author":"Li","year":"2025","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2026.101850_bib130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","article-title":"FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.jhepr.2026.101850_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1172681","article-title":"Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy","volume":"14","author":"Das","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101850_bib132","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","article-title":"Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer","volume":"40","author":"Huang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101850_bib133","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403002121","article-title":"Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer","volume":"121","author":"Amit","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhepr.2026.101850_bib134","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","article-title":"Mesothelin-specific CAR T cells target ovarian cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101850_bib135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41698-026-01292-6","article-title":"Multimodal single-cell profiling reveals crosstalk between macrophages and stromal cells in poor prognostic cholangiocarcinoma patients","volume":"10","author":"Heij","year":"2026","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101850_bib136","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/HEP.0000000000001283","article-title":"Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma","volume":"83","author":"Hong","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101850_bib137","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gutjnl-2023-330748","article-title":"Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy","volume":"73","author":"O'Rourke","year":"2024","journal-title":"Gut"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:53:23Z","timestamp":1785887603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":137,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589555926001217"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101850","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of the stromal and immune microenvironment in intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101850"}}